Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision
Read More
(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision
Read More